The EAU regularly publishes press releases. Other news can be found in the News section or in the EAU News mailing. Stay up to date, and subscribe to the EAU Press Mailing List to receive the latest EAU press releases and other relevant information. Please subscribe here.
We warmly welcome today’s launch of Europe’s Beating Cancer Plan by the European Commission, in particular the planned activities under early detection. The Commission aims to propose an update on the European Council’s Recommendation on cancer screening by 2022, including the potential addition of new cancers such as prostate cancer.
This gives the EU a unique opportunity to tackle the current unacceptable rise in mortality rates and ‘too late’ diagnoses of prostate cancer while avoiding the overdiagnosis and overtreatment challenges of the past and assuring the best possible quality of life for patients. If Europe’s Beating Cancer Plan can harmonise an approach across the EU with regards to early detection of prostate cancer, we believe this will not only decrease mortality from prostate cancer, but also support EU member states to sort out the current mess of opportunistic testing for prostate cancer.
You have been diagnosed with prostate cancer and your doctor gives you the option of not being treated, but of remaining under observation: is there any objective way you can decide to be treated or not treated? What should you do? Now using first results from analysis of the world’s biggest Active Surveillance prostate cancer database, the GAP3 consortium* has begun to identify which patients are at risk of the disease developing and which patients can continue to safely delay treatment. This work is presented at the virtual European Association of Urology congress.
Scientists report a change in why men seek help for sexual problems, with fewer men complaining about impotence (erectile dysfunction) and premature ejaculation, and more men, especially younger men, complaining about low sexual desire and curvature of the penis (Peyronie’s disease).
In the first analysis of its kind, US-based doctors have shown that women who take menopausal hormone therapy (MHT, also known as HRT) have a greater variety of beneficial bacteria in their urine, possibly creating conditions that discourage urinary infections. The study also shows that women who suffer from recurrent urine infections have fewer different types of bacteria in urine than women who don’t have infections, making them more prone to infections.
Findings from the first international prostate cancer quality of life study conducted by patients themselves reports that significant numbers of men treated for the disease are struggling with continence and sexual problems after treatment. Results suggest that any treatment apart from active surveillance may negatively affect quality of life, and indicate that for many men these effects may be greater than previously thought.
Scientists have found a switch which is associated with prostate cancers spreading or forming metastases (secondary tumours). The researchers caution that this work is still at an early stage, and needs further investigation to see if it applies to all prostate cancers. Up to 15% of patients have high risk prostate cancers, potentially leading to significantly increased mortality over time. The work is presented at the virtual European Association of Urology congress.
A study has shown that the amount of porn a man watches is linked to worse erectile function. Watching porn is also associated with greater dissatisfaction with “normal” sex, with only 65% of respondents rating sex with a partner to be more stimulating than porn. This work is presented at the EAU virtual Congress.
Men who receive anti-hormonal treatment after having their prostate removed are 80% more likely to suffer from depression than men who don’t receive this treatment. This leads researchers to suggest that patients receiving androgen deprivation therapy should be monitored for post-surgical depression. This is presented at the European Association of Urology congress in Barcelona.
For the first time, scientists have identified compounds found in coffee which may inhibit the growth of prostate cancer. This is a pilot study, carried out on drug-resistant cancer cells in cell culture and in a mouse model; it has not yet been tested in humans. This work is presented at the European Association of Urology congress in Barcelona, after publication in the peer-reviewed journal The Prostate*.
Patients with prostate, bladder, or kidney cancers are at greater risk of dying if they have had psychiatric care prior to the cancer treatment. In addition, patients with these cancers show greater suicide risk than the general population, even once the data is corrected for previous psychiatric care. These are the main findings of a new study presented at the European Association of Urology congress in Barcelona. They highlight the need for psychiatric care to be integrated into cancer treatment.